PCRX Downgraded by Truist Securities -- Price Target Raised to $
Truist Securities downgraded Pacira BioSciences (PCRX) to 'Hold' from 'Buy' but raised its price target to $36.50. The stock is trading at $36.31, 23.6% above its GF Value™ of $29.39, indicating overvaluation. The company has a GF Score™ of 82/100, showing strong performance but concerns about valuation.
How this was made
The 30-second read
Why it matters
The downgrade reflects analyst concerns about valuation and future performance, potentially prompting short‑term price weakness.
Market read
Analyst rating changes are a common catalyst for short‑term moves in small‑cap biotech stocks.
What to watch
Recent insider sales and high valuation metrics may amplify downside risk.
Background
Pacira BioSciences (PCRX) is a specialty pharmaceutical company focused on non‑opioid pain management. The stock was trading around $36.31 at the time of the downgrade.
Ticker impact
Truist Securities downgraded Pacira BioSciences to Hold and raised the price target to $36.50 on Oct 9 2026.
likely downside pressure as the downgrade outweighs the target increase
Downgrades typically trigger short‑term selling, and the target raise is modest relative to the recent price.
Market effects
May signal broader caution on specialty pharma stocks.
Limited to U.S. biotech/healthcare investors.
Low global impact; primarily affects PCRX shareholders.
Counterpoint
The higher price target could attract buyers despite the downgrade.
Key entities
- AnalystTruist Securities
Provided the downgrade and new price target.
- CompanyPacira BioSciences
Subject of the rating update.
